



011-41195959

Dear Manipal Hospital

We have received a booking request for the details are following. Please provide your confirmation by clicking on the yes button.

Are you sure to confirm the booking?

Name : MR. SOLANKI DIGAMBER KUMAR
 Package Name : Mediwheel Full Body Health Checkup Male Above 40
 Package Code :
 Location : NH-24,Hapur Road,Oppo. Bahmeta Village,Near Lancraft Golf Links Aparment
 Contact Details : 9920542632
 E-mail id : DIGAMBER.SOLANKI@bankofbaroda.com
 Booking Date : 22-02-2024
 Appointment Date : 24-02-2024

Member Information		
Booked Member Name	Age	Gender
MR. SOLANKI DIGAMBER KUMAR	44 year	Male

Please login to your account to confirm the same. Also you mail us for confirmation

Hospital Package Name : Mediwheel Full Body Health Checkup Male Above 40

User Package Name : Mediwheel Full Body Health Checkup Male Above 40

22 Tests included in this Package :

- Stool Test
- Thyroid Profile
- ESR
- Blood Glucose (Fasting)
- General Physician Consultation
- TMT OR 2D ECHO
- Blood Group
- Blood Glucose (Post Prandial)
- Chest X-ray
- ECG
- USG Whole Abdomen
- Eye Check-up consultation
- Urine Sugar Fasting
- Urine Sugar PP
- Dental Consultation
- Urine analysis
- CBC
- HbA1c
- Lipid Profile
- Kidney Profile
- Liver profile
- Prostate Specific Antigen (PSA Male)

Thanks,
Mediwheel Team

You have received this mail because your e-mail ID is registered with This is a system-

Please click on our Terms & Conditions for more information. This email is received because you are register with us [Click here](#) to unsubscribe.

© 2024 - 25, Arcotemi Healthcare Pvt Limited.(Mediwheel)

भारत सरकार
GOVERNMENT OF INDIA



दिगम्बर कुमार सोलंकी
Digamber Kumar Solanki
जन्म तिथि/ DOB: 18/06/1979
पुरुष / MALE



2450 9674 5878

-आम आदमी का अधिकार

भारतीय विशिष्ट पहचान प्राधिकरण
UNIQUE IDENTIFICATION AUTHORITY OF INDIA

पता:

S/O: के. पी. एस. सोलंकी,
मकान न. 258, डी. एम. रोड,
आवास विकास कॉलोनी,
बुलंदशहर, बुलंदशहर,
उत्तर प्रदेश - 203001

Address:

S/O: K. P. S. Solanki, House No. 258,
D. M. Road, Avas Vikas Colony,
Bulandshahr, Bulandshahr,
Uttar Pradesh - 203001


2450 9674 5878

-Aam Admi ka Adhikar

digamber kumar Subanki

- NORMAL ECG -

Unconfirmed Diagnosis



PH100B CL P?

F 60~ 0.15-100 HZ

Chest: 10.0 mm/mV

Limb: 10 mm/mV

Speed: 25 mm/sec

Dev:



RADIOLOGY REPORT

NAME	MR Digamber Kumar SOLANKI	STUDY DATE	24/02/2024 11:22AM
AGE / SEX	44 y / M	HOSPITAL NO.	MH011725749
ACCESSION NO.	R6938869	MODALITY	US
REPORTED ON	24/02/2024 12:11PM	REFERRED BY	HEALTH CHECK MGD

**USG ABDOMEN & PELVIS
FINDINGS**

LIVER: appears normal in size (measures 138 mm) and shape but shows diffuse increase in liver echotexture, in keeping with diffuse grade I fatty infiltration. Rest normal.

SPLEEN: Spleen is normal in size (measures 82 mm), shape and echotexture. Rest normal.

PORTAL VEIN: Appears normal in size and measures 8 mm.

COMMON BILE DUCT: Appears normal in size and measures 3 mm.

IVC, HEPATIC VEINS: Normal.

BILIARY SYSTEM: Normal.

GALL BLADDER: Gall bladder is well distended. Wall thickness is normal and lumen is echofree. Rest normal.

PANCREAS: Pancreas is normal in size, shape and echotexture. Rest normal.

KIDNEYS: Both kidneys are normal in size and shape but show raised renal cortical echotexture. Cortico-medullary differentiation is however maintained. Rest normal.

Right Kidney: measures 92 x 53 mm with parenchymal thickness 13.9 mm.

Left Kidney: measures 93 x 49 mm with parenchymal thickness 12.1 mm.

PELVI-CALYCEAL SYSTEMS: Compact.

NODES: Not enlarged.

FLUID: Nil significant.

URINARY BLADDER: Urinary bladder is well distended. Wall thickness is normal and lumen is echofree. Rest normal.

PROSTATE: Prostate is normal in size, shape and echotexture. It measures 28 x 23 x 22 mm with volume 7 cc. Rest normal.

SEMINAL VESICLES: Normal.

BOWEL: Visualized bowel loops appear normal.

IMPRESSION

-Diffuse grade I fatty infiltration in liver.

-Bilateral raised renal cortical echotexture (ADV:RFT correlation)

Recommend clinical correlation.

**Dr. Monica Shekhawat MBBS, DNB
CONSULTANT RADIOLOGIST**

*****End Of Report*****



RADIOLOGY REPORT

NAME	MR Digamber Kumar SOLANKI	STUDY DATE	24/02/2024 9:47AM
AGE / SEX	44 y / M	HOSPITAL NO.	MH011725749
ACCESSION NO.	R6938868	MODALITY	CR
REPORTED ON	24/02/2024 10:37AM	REFERRED BY	HEALTH CHECK MGD

XR- CHEST PA VIEW

FINDINGS:

LUNGS: Normal.
TRACHEA: Normal.
CARINA: Normal.
RIGHT AND LEFT MAIN BRONCHI: Normal.
PLEURA: Normal.
HEART: Normal.
RIGHT HEART BORDER: Normal.
LEFT HEART BORDER: Normal.
PULMONARY BAY: Normal.
PULMONARY HILA: Normal.
AORTA: Normal.
THORACIC SPINE: Normal.
OTHER VISUALIZED BONES: Normal.
VISUALIZED SOFT TISSUES: Normal.
DIAPHRAGM: Normal.
VISUALIZED ABDOMEN: Normal.
VISUALIZED NECK: Normal.

IMPRESSION:

-No significant abnormality seen.

Please correlate clinically

Dr. Prabhat Prakash Gupta MBBS, DNB, MNAMS
CONSULTANT RADIOLOGIST

*****End Of Report*****



LABORATORY REPORT

Name	: MR DIGAMBER SOLANKI	Age	: 44 Yr(s) Sex :Male
Registration No	: MH011725749	Lab No	: 202402004060
Patient Episode	: H18000001830	Collection Date	: 24 Feb 2024 09:38
Referred By	: HEALTH CHECK MGD	Reporting Date	: 25 Feb 2024 13:11
Receiving Date	: 24 Feb 2024 09:38		

BIOCHEMISTRY

TEST	RESULT	UNIT	BIOLOGICAL REFERENCE INTERVAL
THYROID PROFILE, Serum			Specimen Type : Serum
T3 - Triiodothyronine (ELFA)	1.150	ng/ml	[0.610-1.630]
T4 - Thyroxine (ELFA)	6.340	ug/ dl	[4.680-9.360]
Thyroid Stimulating Hormone	1.900	µIU/mL	[0.250-5.000]

NOTE:

TSH stimulates the thyroid gland to produce the main thyroid hormones T3 and T4. In cases of hyperthyroidism TSH level is severely inhibited and may even be undetectable. In rare forms of high-origin hyperthyroidism, the TSH level is not reduced, since the negative-feedback control of the thyroid hormones has no effect.

In cases of primary hypothyroidism, TSH levels are always much higher than normal and thyroid hormone levels are low.

The TSH assay aids in diagnosing thyroid or hypophysial disorders.

The T4 assay aids in assessing thyroid function, which is characterized by a decrease in thyroxine levels in patients with hypothyroidism and an increase in patients with hyperthyroidism.

The test has been carried out in Fully Automated Immunoassay System VIDAS using ELFA (Enzyme Linked Fluorescence Assay) technology.

**LABORATORY REPORT**

Name : MR DIGAMBER SOLANKI Age : 44 Yr(s) Sex : Male
Registration No : MH011725749 Lab No : 202402004060
Patient Episode : H18000001830 Collection Date : 24 Feb 2024 09:38
Referred By : HEALTH CHECK MGD Reporting Date : 25 Feb 2024 13:06
Receiving Date : 24 Feb 2024 09:38

BLOOD BANK

TEST	RESULT	UNIT	BIOLOGICAL REFERENCE INTERVAL
Blood Group & Rh Typing (Agglutination by gel/tube technique)			Specimen-Blood
Blood Group & Rh typing	O Rh(D) Positive		

Technical note:

ABO grouping and Rh typing is done by cell and serum grouping by microplate / gel technique.

Page 3 of 3

NOTE:

- Abnormal Values

-----END OF REPORT-----

Dr. Charu Agarwal
Consultant Pathologist



Name : MR DIGAMBER SOLANKI
Registration No : MH011725749
Patient Episode : H18000001830
Referred By : HEALTH CHECK MGD
Receiving Date : 24 Feb 2024 09:38

Age : 44 Yr(s) Sex : Male
Lab No : 202402004060
Collection Date : 24 Feb 2024 09:38
Reporting Date : 24 Feb 2024 12:44

HAEMATOTOLOGY

TEST	RESULT	UNIT	BIOLOGICAL REFERENCE INTERVAL
COMPLETE BLOOD COUNT (AUTOMATED)		SPECIMEN-EDTA Whole Blood	
RBC COUNT (IMPEDENCE)	5.31	millions/cumm	[4.50-5.50]
HEMOGLOBIN	15.6	g/dl	[13.0-17.0]
Method: cyanide free SLS-colorimetry			
HEMATOCRIT (CALCULATED)	47.6	%	[40.0-50.0]
MCV (DERIVED)	89.6	fL	[83.0-101.0]
MCH (CALCULATED)	29.4	pg	[25.0-32.0]
MCHC (CALCULATED)	32.8	g/dl	[31.5-34.5]
RDW CV% (DERIVED)	14.7 #	%	[11.6-14.0]
Platelet count	176	x 10 ³ cells/cumm	[150-410]
Method: Electrical Impedance			
MPV (DERIVED)	13.5		
WBC COUNT (TC) (IMPEDENCE)	6.01	x 10 ³ cells/cumm	[4.00-10.00]
DIFFERENTIAL COUNT (VCS TECHNOLOGY/MICROSCOPY)			
Neutrophils	51.0	%	[40.0-80.0]
Lymphocytes	40.0	%	[20.0-40.0]
Monocytes	6.0	%	[2.0-10.0]
Eosinophils	3.0	%	[1.0-6.0]
Basophils	0.0	%	[0.0-2.0]
ESR	10.0	mm/1sthour	[0.0-



Name : MR DIGAMBER SOLANKI
Registration No : MH011725749
Patient Episode : H18000001830
Referred By : HEALTH CHECK MGD
Receiving Date : 24 Feb 2024 15:49

Age : 44 Yr(s) Sex :Male
Lab No : 202402004060
Collection Date : 24 Feb 2024 15:49
Reporting Date : 25 Feb 2024 13:39

CLINICAL PATHOLOGY

ROUTINE URINE ANALYSIS (Semi Automated) Specimen-Urine

MACROSCOPIC DESCRIPTION

Colour	PALE YELLOW	(Pale Yellow - Yellow)
Appearance	CLEAR	
Reaction[pH]	5.0	(4.6-8.0)
Specific Gravity	1.005	(1.003-1.035)

CHEMICAL EXAMINATION

Protein/Albumin	Negative	(NEGATIVE)
Glucose	NIL	(NIL)
Ketone Bodies	Negative	(NEGATIVE)
Urobilinogen	NORMAL	(NORMAL)

MICROSCOPIC EXAMINATION (Automated/Manual)

Pus Cells	2-3/hpf	(0-5/hpf)
RBC	0-1/hpf	(0-2/hpf)
Epithelial Cells	1-2 /hpf	
CASTS	NIL	
Crystals	NIL	
Bacteria	NIL	
OTHERS	NIL	



LABORATORY REPORT



Name : MR DIGAMBER SOLANKI
Registration No : MH011725749
Patient Episode : H18000001830
Referred By : HEALTH CHECK MGD
Receiving Date : 24 Feb 2024 09:38

Age : 44 Yr(s) Sex : Male
Lab No : 202402004060
Collection Date : 24 Feb 2024 09:38
Reporting Date : 25 Feb 2024 13:29

BIOCHEMISTRY

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

Glycosylated Hemoglobin

Specimen: EDTA

HbA1c (Glycosylated Hemoglobin)

Method: HPLC

5.9 # %

[0.0-5.6]

As per American Diabetes Association (ADA)
HbA1c in %
Non diabetic adults ≥ 18 years < 5.7
Prediabetes (At Risk) 5.7-6.4
Diagnosing Diabetes ≥ 6.5

Estimated Average Glucose (eAG) 123 mg/dl

Comments : HbA1c provides an index of average blood glucose levels over the past 8-12 weeks and is a much better indicator of long term glycemic control.

Serum LIPID PROFILE

Serum TOTAL CHOLESTEROL

Method: Oxidase, esterase, peroxide

182 mg/dl

[<200]

Moderate risk: 200-239

High risk: > 240

[<150]

Borderline high: 151-199

High: 200 - 499

Very high: > 500

[35.0-65.0]

TRIGLYCERIDES (GPO/POD)

110 mg/dl

HDL- CHOLESTEROL

Method : Enzymatic Immunoimhibition

58.0 mg/dl

VLDL- CHOLESTEROL (Calculated)

22 mg/dl

CHOLESTEROL, LDL, CALCULATED

102.0 mg/dl

[0-35]

[<120.0]

Near/

Borderline High: 130-159

High Risk: 160-189

Above optimal-100-129



LABORATORY REPORT



Name : MR DIGAMBER SOLANKI
Registration No : MH011725749
Patient Episode : H18000001830
Referred By : HEALTH CHECK MGD
Receiving Date : 24 Feb 2024 09:38

Age : 44 Yr(s) Sex : Male
Lab No : 202402004060
Collection Date : 24 Feb 2024 09:38
Reporting Date : 24 Feb 2024 12:16

BIOCHEMISTRY

TEST	RESULT	UNIT	BIOLOGICAL REFERENCE INTERVAL
T.Chol/HDL.Chol ratio (Calculated)	3.1		<4.0 Optimal 4.0-5.0 Borderline >6 High Risk
LDL.CHOL/HDL.CHOL Ratio (Calculated)	1.8		<3 Optimal 3-4 Borderline >6 High Risk

Note:

Reference ranges based on ATP III Classifications.

Lipid profile is a panel of blood tests that serves as initial broad medical screening tool for abnormalities in lipids, the results of this tests can identify certain genetic diseases and determine approximate risks for cardiovascular disease, certain forms of pancreatitis and other diseases

KIDNEY PROFILE

Specimen: Serum			
UREA	18.8	mg/dl	[15.0-40.0]
Method: GLDH, Kinatic assay			
BUN, BLOOD UREA NITROGEN	8.8	mg/dl	[8.0-20.0]
Method: Calculated			
CREATININE, SERUM	0.83	mg/dl	[0.70-1.20]
Method: Jaffe rate-IDMS Standardization			
URIC ACID	5.8	mg/dl	[4.0-8.5]
Method: uricase PAP			
SODIUM, SERUM	139.00	mmol/L	[136.00-144.00]
POTASSIUM, SERUM	4.96	mmol/L	[3.60-5.10]
SERUM CHLORIDE	107.3	mmol/L	[101.0-111.0]
Method: ISE Indirect			



Name : MR DIGAMBER SOLANKI
Registration No : MH011725749
Patient Episode : H18000001830
Referred By : HEALTH CHECK MGD
Receiving Date : 24 Feb 2024 09:38

Age : 44 Yr(s) Sex :Male
Lab No : 202402004060
Collection Date : 24 Feb 2024 09:38
Reporting Date : 24 Feb 2024 12:16

BIOCHEMISTRY

TEST	RESULT	UNIT	BIOLOGICAL REFERENCE INTERVAL
eGFR (calculated)	107.0	ml/min/1.73sq.m	[>60.0]
<p>Technical Note eGFR which is primarily based on Serum Creatinine is a derivation of CKD-EPI 2009 equation normalized to 1.73 sq.m BSA and is not applicable to individuals below 18 years. eGFR tends to be less accurate when Serum Creatinine estimation is indeterminate e.g. patients at extremes of muscle mass, on unusual diets etc. and samples with severe Hemolysis Icterus / Lipemia.</p>			

LIVER FUNCTION TEST

BILIRUBIN - TOTAL Method: D P D	0.59	mg/dl	[0.30-1.20]
BILIRUBIN - DIRECT Method: DPD	0.11	mg/dl	[0.00-0.30]
INDIRECT BILIRUBIN (SERUM) Method: Calculation	0.48	mg/dl	[0.10-0.90]
TOTAL PROTEINS (SERUM) Method: BIURET	7.10	gm/dl	[6.60-8.70]
ALBUMIN (SERUM) Method: BCG	4.63	g/dl	[3.50-5.20]
GLOBULINS (SERUM) Method: Calculation	2.50	gm/dl	[1.80-3.40]
PROTEIN SERUM (A-G) RATIO Method: Calculation	1.87		[1.00-2.50]
AST (SGOT) (SERUM) Method: IFCC W/O P5P	26.00	U/L	[0.00-40.00]



Name : MR DIGAMBER SOLANKI
Registration No : MH011725749
Patient Episode : H18000001830
Referred By : HEALTH CHECK MGD
Receiving Date : 24 Feb 2024 09:38

Age : 44 Yr(s) Sex : Male
Lab No : 202402004060
Collection Date : 24 Feb 2024 09:38
Reporting Date : 24 Feb 2024 12:16

BIOCHEMISTRY

TEST	RESULT	UNIT	BIOLOGICAL REFERENCE INTERVAL
ALT (SGPT) (SERUM) Method: IFCC W/O P5P	41.20	U/L	[17.00-63.00]
Serum Alkaline Phosphatase Method: AMP BUFFER IFCC)	63.0	IU/L	[32.0-91.0]
GGT	32.0	U/L	[7.0-50.0]

Liver function test aids in diagnosis of various pre hepatic, hepatic and post hepatic causes of dysfunction like hemolytic anemia's, viral and alcoholic hepatitis and cholestasis of obstructive causes.

The test encompasses hepatic excretory, synthetic function and also hepatic parenchymal cell damage. LFT helps in evaluating severity, monitoring therapy and assessing prognosis of liver disease and dysfunction.

-----END OF REPORT-----

Dr. Alka Dixit Vats
Consultant Pathologist



LABORATORY REPORT

Name : MR DIGAMBER SOLANKI
Registration No : MH011725749
Patient Episode : H18000001830
Referred By : HEALTH CHECK MGD
Receiving Date : 24 Feb 2024 09:38

Age : 44 Yr(s) Sex :Male
Lab No : 202402004061
Collection Date : 24 Feb 2024 09:38
Reporting Date : 24 Feb 2024 12:17

BIOCHEMISTRY

TEST	RESULT	UNIT	BIOLOGICAL REFERENCE INTERVAL
GLUCOSE-Fasting Specimen: Plasma GLUCOSE, FASTING (F) Method: Hexokinase	99.0	mg/dl	[70.0-110.0]

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

Increased in Diabetes mellitus, Cushing's syndrome (10-15%), chronic pancreatitis (30%).
Drugs corticosteroids, phenytoin, estrogen, thiazides

Decreased in Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy(adrenocortical, stomach, fibro sarcoma), infant of a diabetic mother enzyme deficiency diseases(e.g.galactosemia),
Drugs-
insulin, ethanol, propranolol, sulfonylureas, tobutamide, and other oral hypoglycemic agents.

-----END OF REPORT-----

Dr. Alka Dixit Vats
Consultant Pathologist



LABORATORY REPORT

Name : MR DIGAMBER SOLANKI
Registration No : MH011725749
Patient Episode : H18000001830
Referred By : HEALTH CHECK MGD
Receiving Date : 24 Feb 2024 15:48

Age : 44 Yr(s) Sex : Male
Lab No : 202402004062
Collection Date : 24 Feb 2024 15:48
Reporting Date : 25 Feb 2024 13:19

BIOCHEMISTRY

TEST	RESULT	UNIT	BIOLOGICAL REFERENCE INTERVAL
PLASMA GLUCOSE Specimen: Plasma GLUCOSE, POST PRANDIAL (PP), 2 HOURS Method: Hexokinase Note: Conditions which can lead to lower postprandial glucose levels as compared to fasting glucose are excessive insulin release, rapid gastric emptying, brisk glucose absorption , post exercise	101.0	mg/dl	[80.0-140.0]

-----END OF REPORT-----

Dr. Charu Agarwal
Consultant Pathologist